J. Wort (London, United Kingdom), K. Olsson (Hannover, Germany), L. Savale (Le Kremlin Bicêtre, France), S. Mathai (Baltimore, United States of America)
Respiratory muscle function in pulmonary hypertension improves following exercise and respiratory training
H. J. Kabitz, H. C. Bremer, A. Schwoerer, F. Sonntag, S. Walterspacher, D. Walker, N. Ehlken, G. Staehler, W. Windisch, E. Grünig (Freiburg, Donaueschingen, Heidelberg, Loewenstein, Köln, Germany)
|  |
Right heart catheterization in elderly patients with suspected pre-capillary pulmonary hypertension
T. Lamon, G. Prévot, L. Têtu, A. Didier (Toulouse, France)
| |
Predictive value of 6 MWD and derived indices 3 months after initial PAH therapy for the necessity of a combination therapy in patients with pulmonary arterial hypertension
D. Korte, A. Rolf, W. Seeger, A. Ghofrani, R. Voswinckel (Giessen, Bad Nauheim, Germany)
| |
An open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH)
A. Waxman, A. Opotowsky, L. Lawler, D. Systrom (Boston, United States Of America)
|  |
Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH)
O. Sitbon, R. Channick, M. Delcroix, N. Galiè, H. A. Ghofrani, P. Jansa, F. O. Le Brun, S. Mehta, L. Perchenet, T. Pulido, B. K. S. Sastry, R. Souza, A. Torbicki, L. Rubin, G. Simonneau (Le Kremlin Bicêtre, France; Boston, San Diego, United States Of America; Leuven, Belgium; Bologna, Italy; Giessen, Germany; Prague, Czech Republic; Allschwil, Switzerland; London, Canada; Mexico City, Mexico; Hyderabad, India; São Paulo, Brazil; ECZ-Otwock, Poland)
| |
The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension
J. van Campen, K. de Boer, M. Wagenaar, L. Handoko, C. Allaart, A. C. van Rossum, F. de Man, H. J. Bogaard, A. Vonk Noordegraaf (Amsterdam, Netherlands)
| |
The effect of treatment on right ventriculo-arterial coupling in idiopathic pulmonary arterial hypertension
C. E. E. van der Bruggen, P. Trip, F. S. de Man, H. J. Bogaard, N. Westerhof, A. Vonk Noordegraaf (Amsterdam, Netherlands)
| |
Do phosphodiesterase 5 inhibitors improve exercise capacity in patients with COPD associated pulmonary hypertension? (3P study)
A. Goudie, P. Hopkinson, B. Lipworth, A. Struthers (Dundee, United Kingdom)
| |
Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension
D. Renard, T. Bouillon, G. Flesch, P. Zhou, D. Quinn (Basel, Switzerland; Horsham, United Kingdom; East Hanover, United States Of America)
| |
Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension
T. Bouillon, D. Renard, P. Zhou, G. Flesch, D. Quinn (Basel, Switzerland; Horsham, United Kingdom; East Hanover, United States Of America)
| |
Effect of nocturnal oxygen and acetazolamide on exercise performance in patients with precapillary pulmonary hypertension and sleep disturbed breathing. Randomized, double-blind, cross-over trial
S. Ulrich, S. Keusch, F. Hildenbrand, C. Lo Casio, L. Huber, F. Tanner, R. Speich, K. Bloch (Zurich, Switzerland)
| |
Switch of patients with pulmonary arterial hypertension after withdrawal of the endothelin receptor antagonist sitaxentan
D. Pittrow, A. Ghofrani, S. Rosenkranz, E. Grünig, D. Huscher, H. Tiede, M. Delcroix, G. Stähler, M. Halank, M. Held, C. Grohé, T. J. Lange, J. Behr, H. Klose, H. Wilkens, R. Speich, C. M. Kähler, A. Filusch, M. Germann, R. Ewert, H. J. Seyfarth, K. M. Olsson, C. F. Opitz, S. P. Gaine, C. D. Vizza, A. Vonk-Noordegraaf, H. Kaemmerer, J. S. R. Gibbs, O. Distler, C. Schweiger, M. M. Hoeper (Dresden, Giessen, Cologne, Heidelberg, Berlin, Hannover, Loewenstein, Würzburg, Regensburg, Munich, Hamburg, Homburg, Freiburg, Greifswald, Leipzig, Duisburg-Essen, Germany; Leuven, Belgium; Zurich, Switzerland; Innsbruck, Austria; Dublin, Ireland; Rome, Italy; Amsterdam, Netherlands; London, United Kingdom)
| |
Pharmacokinetic (PK) interaction of ketoconazole (KC), clarithromycin (CM) and midazolam (MZ) with riociguat
C. Becker, R. Frey, S. Unger, D. Thomas, M. Reber, G. Weimann, H. Dietrich, E. R. Arens, W. Mueck (Wuppertal, Cologne, Germany)
| |
Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan
T. McWilliams, K. Whyte, C. Stewart, A. Coverdale, C. Wasywich (Auckland, New Zealand)
| |
Central venous catheter infections in out-patients with pulmonary hypertension treated with continuous iloprost
S. Keusch, R. Speich, S. Ulrich Somaini (Zurich, Switzerland)
| |
Acute and chronic effects of PDE5-Is on SpO2 in patients with COPD associated pulmonary hypertension
A. Goudie, P. Hopkinson, B. Lipworth, A. Struthers (Dundee, United Kingdom)
| |
Hemodynamic correlates of right ventricular afterload and pulmonary artery pulsatility under treatment with prostacyclin: Retrospective analysis of changes from baseline in pulmonary arterial hypertension
C. Gerges, M. Gerges, Y. Zhou, D. Lam, M. Lang, I. Lang (Vienna, Austria; Research Triangle Park, United States Of America)
| |
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
R. Frey, C. Becker, S. Unger, A. Schmidt, G. Wensing, W. Mueck (Wupperal, Wuppertal, Germany)
| |
Inhaled iloprost did not influence cytokines levels in patients with different forms of pulmonary hypertension
V. Bystrov, T. Martynyuk, O. Arhipova, V. Masenko, I. Chasova (Moscow, Russian Federation)
| |
Impact of macitentan on the health-related quality of life (HRQoL) in pulmonary arterial hypertension (PAH): Results from a long-term randomised controlled trial
P. Jansa, R. Channick, M. Delcroix, N. Galiè, H. A. Ghofrani, E. Hunche, S. Mehta, C. Mittelholzer, T. Pulido, B. K. S. Sastry, O. Sitbon, R. Souza, A. Torbicki, G. Simonneau, L. Rubin (Prague, Czech Republic; Boston, San Diego, United States Of America; Leuven, Belgium; Bologna, Italy; Giessen, Germany; Allschwil, Switzerland; London, Canada; Mexico City, Mexico; Hyderabad, India; Le Kremlin Bicêtre, France; São Paulo, Brazil; ECZ-Otwock, Poland)
| |